Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 10, 2009, Pages 1147-1153

  Chong, Benjamin F ^a   Mohan, Chandra ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Chemokine; Lupus; Lupus nephritis

Indexed keywords

8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CTCE 9908; EFALIZUMAB; NATALIZUMAB; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DISEASE SEVERITY; DOWN REGULATION; DROWSINESS; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; INJECTION SITE REACTION; LEUKOCYTE; LUPUS ERYTHEMATOSUS NEPHRITIS; METASTASIS; NEPHRITIS; NONHODGKIN LYMPHOMA; NONHUMAN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SINUS TACHYCARDIA; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

CHEMOKINE CXCL12; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, CXCR4;

EID: 70349397424     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220903196761     Document Type: Review

References (74)

1. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007;369:587-596
2. Madhok R, Wu O. Systemic lupus erythematosus. Am Fam Physician 2007;76:1351-1353
3. Ippolito A, Petri M. An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol 2008;26:S72-9 (Pubitemid 351798718)
4. Suzuki N, Sakane T, Engleman EG. Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus. J Clin Invest 1990;85:238-247 (Pubitemid 20030315)
5. Chan OT, Hannum LG, Haberman AM, et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999;189:1639-1648
6. Blenman KR, Duan B, Xu Z, et al. IL-10 regulation of lupus in the NZM2410 murine model. Lab Invest 2006;86:1136-1148 (Pubitemid 44624150)
7. Tanaka Y, Saito K, Shirakawa F, et al. Production of B cell-stimulating factors by B cells in patients with systemic lupus erythematosus. J Immunol 1988;141:3043-3049 (Pubitemid 18252110)
8. Liossis SN, Kovacs B, Dennis G, et al. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 1996;98:2549-2557 (Pubitemid 26415075)
9. Hibbs ML, Tarlinton DM, Armes J, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995;83:301-311
10. Kumar KR, Li L, Yan M, et al. Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science 2006;312:1665-1669 (Pubitemid 43902668)
11. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-2589 (Pubitemid 39062719)
12. Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-2677 (Pubitemid 36118931)
13. Inghirami G, Simon J, Balow JE, Tsokos GC. Activated T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus induce B cells to produce immunoglobulin. Clin Exp Rheumatol 1988;6:269-276 (Pubitemid 18256224)
14. Prud'Homme GJ, Park CL, Fieser TM, et al. Identification of a B cell differentiation factor(s) spontaneously produced by proliferating T cells in murine lupus strains of the lpr/lpr genotype. J Exp Med 1983;157:730-742
15. Santoro TJ, Portanova JP, Kotzin BL. The contribution of L3T4+ T cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice. J Exp Med 1988;167:1713-1718
16. Ando DG, Sercarz EE, Hahn BH. Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model. J Immunol 1987;138:3185-3190
17. Budagyan VM, Bulanova EG, Sharova NI, et al. The resistance of activated T-cells from SLE patients to apoptosis induced by human thymic stromal cells. Immunol Lett 1998;60:1-5
18. Vassilopoulos D, Kovacs B, Tsokos GC. TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol 1995;155:2269-2281
19. Blasini AM, Alonzo E, Chacon R, et al. Abnormal pattern of tyrosine phosphorylation in unstimulated peripheral blood T lymphocytes from patients with systemic lupus erythematosus. Lupus 1998;7:515-523 (Pubitemid 28542626)
20. Bahjat FR, Pine PR, Reitsma A, et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008;58:1433-1444 (Pubitemid 351705932)
21. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-1227
22. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-66
23. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 2002;283:R7-28 (Pubitemid 34863907)
24. Bai Z, Hayasaka H, Kobayashi M, et al. CXC chemokine ligand 12 promotes CCR7-dependent naive T cell trafficking to lymph nodes and Peyer's patches. J Immunol 2009;182:1287-1295
25. Bleul CC, Fuhlbrigge RC, Casasnovas JM, et al. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996;184:1101-1109
26. Vicente-Manzanares M, Montoya MC, Mellado M, et al. The chemokine SDF-1α triggers a chemotactic response and induces cell polarization in human B lymphocytes. Eur J Immunol 1998;28:2197-2207 (Pubitemid 28321304)
27. Brandes M, Legler DF, Spoerri B, et al. Activation-dependent modulation of B lymphocyte migration to chemokines. Int Immunol 2000;12:1285-1292 (Pubitemid 30657772)
28. D'Apuzzo M, Rolink A, Loetscher M, et al. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol 1997;27:1788-1793 (Pubitemid 27302865)
29. Yu L, Cecil J, Peng SB, et al. Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene 2006;374:174-179 (Pubitemid 43750309)
30. Peled A, Kollet O, Ponomaryov T, et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34+ cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000;95:3289-3296
31. Nanki T, Lipsky PE. Cutting edge: stromal cell-derived factor-1 is a costimulator for CD4+ T cell activation. J Immunol 2000;164:5010-5014 (Pubitemid 30305170)
32. Forster R, Kremmer E, Schubel A, et al. Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. J Immunol 1998;160:1522-1531 (Pubitemid 28093457)
33. Granelli-Piperno A, Moser B, Pope M, et al. Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors. J Exp Med 1996;184:2433-2438 (Pubitemid 27023745)
34. Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996;382:635-638 (Pubitemid 26268957)
35. Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998;393:595-599 (Pubitemid 28319251)
36. Odemis V, Lamp E, Pezeshki G, et al. Mice deficient in the chemokine receptor CXCR4 exhibit impaired limb innervation and myogenesis. Mol Cell Neurosci 2005;30:494-505 (Pubitemid 41721168)
37. Ganju RK, Brubaker SA, Meyer J, et al. The α-chemokine, stromal cell-derived factor-1α, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem 1998;273:23169-23175 (Pubitemid 28417500)
38. Vila-Coro AJ, Rodriguez-Frade JM, Martin De Ana A, et al. The chemokine SDF-1α triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J 1999;13:1699-1710
39. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877
40. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-974 (Pubitemid 24303213)
41. Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the liga nd for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996;382:833-835 (Pubitemid 26299571)
42. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996;382:829-833 (Pubitemid 26299570)
43. Iwasaki Y, Akari H, Murakami T, et al. Efficient inhibition of SDF-1α-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists. Cancer Sci 2009;100:778-781
44. Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 2003;100:4185-4190 (Pubitemid 36418178)
45. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37:1253-1262
46. Crazzolara R, Kreczy A, Mann G, et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol 2001;115:545-553 (Pubitemid 34015643)
47. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56 (Pubitemid 32225831)
48. Geminder H, Sagi-Assif O, Goldberg L, et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001;167:4747-4757 (Pubitemid 32954357)
49. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004;14:171-179 (Pubitemid 38586742)
50. Scotton CJ, Wilson JL, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002;62:5930-5938 (Pubitemid 35204756)
51. Zhou Y, Larsen PH, Hao C, Yong VW. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 2002;277:49481-49487 (Pubitemid 36014384)
52. Liang Z, Brooks J, Willard M, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 2007;359:716-722 (Pubitemid 46908803)
53. Ping YF, Yao XH, Chen JH, et al. The anti-cancer compound Nordy inhibits CXCR4-mediated production of IL-8 and VEGF by malignant human glioma cells. J Neurooncol 2007;84:21-29
54. Richert MM, Vaidya KS, Mills CN, et al. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 2009;21:761-767
55. Kim SY, Lee CH, Midura BV, et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 2008;25:201-211
56. Wong D, Korz W. Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer Res 2008;14:7975-7980
57. Matthys P, Hatse S, Vermeire K, et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-γ receptor-deficient mice. J Immunol 2001;167:4686-4692 (Pubitemid 32954350)
58. De Klerck B, Geboes L, Hatse S, et al. Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis. Arthritis Res Ther 2005;7:R1208-20
59. Kohler RE, Comerford I, Townley S, et al. Antagonism of the chemokine receptors CXCR3 and CXCR4 reduces the pathology of experimental autoimmune encephalomyelitis. Brain Pathol 2008;18:504-516
60. Wang A, Fairhurst AM, Tus K, et al. CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus. J Immunol 2009;182:4448-4458
61. Mendlovic S, Brocke S, Shoenfeld Y, et al. Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proc Natl Acad Sci USA 1988;85:2260-2264 (Pubitemid 24315870)
62. Eilat E, Dayan M, Zinger H, Mozes E. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. Proc Natl Acad Sci USA 2001;98:1148-1153 (Pubitemid 32121201)
63. Sela U, Hershkoviz R, Cahalon L, et al. Down-regulation of stromal cell-derived factor-1α-induced T cell chemotaxis by a peptide based on the complementarity-determining region 1 of an anti-DNA autoantibody via up-regulation of TGF-β secretion. J Immunol 2005;174:302-309 (Pubitemid 40007417)
64. Balabanian K, Couderc J, Bouchet-Delbos L, et al. Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J Immunol 2003;170:3392-3400 (Pubitemid 36302219)
65. Robak E, Kulczycka L, Sysa-Jedrzejowska A, et al. Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus. Eur Cytokine Netw 2007;18:181-187
66. Fritsch RD, Shen X, Illei GG, et al. Abnormal differentiation of memory T cells in systemic lupus erythematosus. Arthritis Rheum 2006;54:2184-2197 (Pubitemid 44051075)
67. Henneken M, Dorner T, Burmester GR, Berek C. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 2005;7:R1001-13
68. Amoura Z, Combadiere C, Faure S, et al. Roles of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares. Arthritis Rheum 2003;48:3487-3496 (Pubitemid 37531914)
69. Meller S, Winterberg F, Gilliet M, et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 2005;52:1504-1516 (Pubitemid 40663942)
70. Stewart DA, Smith C, MacFarland R, Calandra G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant 2009;15:39-46
71. Stone ND, Dunaway SB, Flexner C, et al. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother 2007;51:2351-2358 (Pubitemid 47047310)
72. Sobell JM, Weinberg JM. Patient fatalities potentially associated with efalizumab use. J Drugs Dermatol 2009;8:215
73. Goodin DS, Cohen BA, O'Connor P, et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;71:766-773
74. Davis JC, Tassiulas IO, Boumpas DT. Lupus nephritis. Curr Opin Rheumatol 1996;8:415-423